V8 Diagnostic Ultrasound System, V7 Diagnostic Ultrasound System

The Samsung V8 and V7 Diagnostic Ultrasound Systems are designed to acquire multi-modal ultrasound images and analyze body fluids for a broad spectrum of clinical diagnostic applications, utilizing various imaging modes and specialized transducers. These systems integrate advanced Artificial Intelligence through features like NerveTrack, BiometryAssist, ViewAssist, and HeartAssist, which employ deep learning for automated anatomical detection, segmentation, and measurement, validated through non-clinical testing with a focus on accuracy and performance.

The Samsung V8 and V7 are mobile, software-controlled diagnostic ultrasound systems designed to acquire and display ultrasound data for a wide array of clinical applications. These applications span fetal/obstetrics, abdominal, gynecological, intra-operative, pediatric, small organ, cephalic (neonatal and adult), trans-rectal, trans-vaginal, musculoskeletal, urological, cardiac (adult and pediatric), thoracic, trans-esophageal (cardiac), and peripheral vessel imaging. The systems support multiple operational modes including 2D, M-mode, Color, Power, Pulsed Wave, and Continuous Wave Doppler, Tissue Doppler Imaging (TDI/TDW), ElastoScan, and combined 3D/4D imaging, facilitating comprehensive diagnostic assessments by qualified healthcare professionals. Technological advancements in the V8 and V7 systems include the integration and expansion of Artificial Intelligence (AI) features such as NerveTrack (for detecting nerves like Greater Occipital, Sciatic, Common Peroneal, Tibial), BiometryAssist (automating fetal biometry), ViewAssist (for fetal view recognition and anatomical annotation), and HeartAssist (for AI-based cardiac assessment in fetal and adult patients). These AI tools, validated through non-clinical testing against expert ground truths for accuracy and speed, aim to enhance diagnostic efficiency. The systems also incorporate new transducers (miniER7; V7 only: LA4-18AD, EV2-11ARE, EV2-11AVE, CV1-8AE) and migrate others (PA4-12B, LA2-9S; V7 only: LA3-14AD), expanding imaging capabilities, with all new patient-contacting components undergoing biocompatibility testing.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. How does the performance of the AI-driven NerveTrack, BiometryAssist, ViewAssist, and HeartAssist features compare to traditional manual methods in terms of accuracy, time-efficiency, and inter-observer variability in real-world clinical settings?; Given the demographic limitations noted in the testing data (e.g., 'All Koreans' for NerveTrack), what steps are planned to validate or adapt these AI algorithms for broader, more diverse patient populations to ensure equitable performance?; What are the specific image acquisition protocols or quality thresholds recommended to ensure optimal input for the AI-based analysis features, and how do the systems guide users to meet these?; Could the AI algorithms, particularly HeartAssist and BiometryAssist, be further trained to detect subtle pathological indicators beyond standard anatomical measurements and view classifications?; For the NerveTrack feature, what is the typical depth penetration limit for reliable nerve detection across the expanded nerve types, especially in patients with higher BMI where tissue attenuation can be a challenge?